Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Edward Metzger

Pain Medicine Lynchburg, VA Medical Doctor

NPI 1013972462 CMS profile 875923

1922 Thomson Drive, Suite D, Lynchburg, VA 24501

Open in the dashboard

General payments

$3,137

205 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edward Metzger of Lynchburg, VA is reported in the CMS Open Payments database as having received $3,137 across 205 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 56th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,326 69
2024 General $606 46
2023 General $445 31
2022 General $538 40
2021 General $198 17
2020 General $23 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edward Metzger
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Edward Metzger were reported at $1,326. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Edward Metzger Pain Medicine median Middle half National median
2019 $0 $498 $126–$1,682 $163
2020 $23 $284 $80–$910 $114
2021 $198 $399 $112–$1,219 $132
2022 $538 $455 $137–$1,484 $149
2023 $445 $484 $128–$1,495 $160
2024 $606 $498 $131–$1,540 $164
2025 $1,326 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AbbVie, Inc. $1,186 98 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $497 30 payments
  3. Janssen Biotech, Inc. $452 22 payments
  4. Regeneron Healthcare Solutions, Inc. $164 7 payments
  5. Aimmune Therapeutics, Inc. $147 8 payments
  6. Ardelyx, Inc. $144 8 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $110 6 payments
  8. Ipsen Biopharmaceuticals, Inc $109 5 payments
  9. Intercept Pharmaceuticals, Inc. $81 5 payments
  10. Braintree Laboratories, Inc. $49 4 payments
  11. Other $199 12 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $3,137 205 payments
Products named General payments · program years 2020–2025
  1. RINVOQ $662 52 payments
  2. ENTYVIO $417 26 payments
  3. TREMFYA $367 17 payments
  4. SKYRIZI Immunology $322 16 payments
  5. STELARA $300 14 payments
  6. SKYRIZI Immunology $298 29 payments
  7. SIMPONI ARIA $280 13 payments
  8. SIMPONI $280 13 payments
  9. LINZESS $206 15 payments
  10. HUMIRA $189 16 payments
  11. Other $1,458 85 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$45,346

Medicare's payments for the services billed

Medicare patients

456

Average age 72

Services billed

465

256 women, 200 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 38%
Diabetes 24%
Chronic kidney disease 22%
Cancer 16%
Ischemic heart disease 13%
Depression 12%
Atrial fibrillation 9%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $134
$134 — —
SKYRIZI
  • AbbVie, Inc. $80
$80 — —
IQIRVO
  • Ipsen Biopharmaceuticals, Inc $68
$68 — —
ZENPEP
  • AIMMUNE THERAPEUTICS, INC. $66
$66 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $47
$47 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

205 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record